Cancer News
Scientists Map Complete Genetic Blueprint Of Deadly Cancers In what has been heralded as a significant breakthrough in the fight against two of the world's deadliest cancers, US scientists have mapped complete genetic blueprints comprising more than 20,000 genes in 24 pancreatic cancers and 22 brain cancers, including not only individual gene mutations but also their interlinked pathways which sustain tumour development and growth. |
OncoMune Publishes Positive Results Of OCM-8054 - Breast Cancer Dependency On BORIS Unequivocally Demonstrated By RNA Interference OncoMune LLC, a biotechnology company focused on developing targeted cancer therapeutics, announced the publication of its preclinical OCM-8054 data. The publication entitled, "Selective apoptosis of breast cancer cells by siRNA targeting of BORIS," appeared in the May 23rd 2008 issue of the scientific journal, Biochemical and Biophysical Research Communications, Volume 370, Issue 1, Pages 109-112. |
HIV And Prostate Cancer: A Systematic Review Of The Literature UroToday.com - In the online edition of Prostate Cancer Prostatic Diseases, Dr. Jonathan Silberstein and his colleagues presented a systematic review of HIV and prostate cancer (CaP). The message that may be underappreciated by the urology community is the excellent longevity of HIV patients, which clearly impacts their potential for diagnosis and management of CaP. In 2003, over one-million people were living with HIV in the US and three quarters of them were men. |
September 13th Is National Childhood Cancer Awareness Day A pediatric bone cancer survivor who now is studying to become a pediatric hematologist/oncologist…a childhood leukemia survivor who has walked a mile in the shoes of the young cancer patients she now treats. These are just a few of the hundreds of patients treated through the Pediatric Hematology/Oncology program at The Cancer Institute of New Jersey (CINJ), which is celebrating 15 years of patient care this year. |
Scientists 'Stand Up To Cancer' With Latest Research As the Stand Up To Cancer campaign -- being put forth by television's "Big 3" networks -- is opening the nation's eyes to the need and the benefit of cancer research dollars, The Cancer Institute of New Jersey (CINJ) is highlighting some of its groundbreaking studies being conducted by internationally recognized clinical investigators. |
Medarex Announces Presentations At The 33rd Congress Of The European Society For Medical Oncology Medarex, Inc. (Nasdaq: MEDX) announced that nine clinical abstracts for ipilimumab, an investigational anti-CTLA-4 antibody, in melanoma are scheduled to be the subject of presentations at the 33rd Congress of the European Society for Medical Oncology (ESMO) being held September 12-16, 2008 in Stockholm. |
Azaya Therapeutics Licenses Promising Treatment For Head And Neck Cancers Azaya Therapeutics, Inc., announced that it has signed a licensing agreement to further develop a breakthrough technology that uses liposomes to deliver radiation through direct injection into head and neck tumors, shrinking the tumor, delaying recurrence and avoiding the collateral tissue damage that often accompanies all other forms of radiation therapy. The company plans to begin a phase I clinical trial in early 2010. |
Nanoscale Droplets With Cancer-Fighting Implications Produced By Scientists UCLA scientists have succeeded in making unique nanoscale droplets that are much smaller than a human cell and can potentially be used to deliver pharmaceuticals. "What we found that was unexpected was within each oil droplet there was also a water droplet - a double emulsion," said Timothy Deming, professor and chair of the UCLA Department of Bioengineering and a member of both the California NanoSystems Institute (CNSI) at UCLA and UCLA's Jonsson Cancer Center. |
Blood 'Fingerprints' For Cancer Serum microRNAs (miRNAs) can serve as biomarkers for the detection of diseases including cancer and diabetes, according to research published online this week in Cell Research. The findings pave the way for a revolutionary non-invasive diagnostic tool. miRNAs are a class of naturally occurring small non-coding RNAs that have been linked with cancer development. |
Evident™ Microwave Ablation System Offers Surgical Oncologists And Interventional Radiologists Fast, Efficient Tool To Ablate Soft Tissue Covidien (NYSE: COV, BSX: COV), a world leader in advanced energy-based surgical systems, today announced the global release of the Evident™ microwave ablation system. Physicians now have a powerful new tool with industry-leading technology to ablate soft tissue. The Evident™ microwave ablation system received 510(k) clearance from the United States Food and Drug Administration for use in soft tissue, and is now the first microwave ablation system available globally. |
News From CA: Cancer Quality Alliance, Blueprint For A Better Cancer Care System Cancer Quality Alliance: Blueprint for a Better Cancer Care System In this report, the Cancer Quality Alliance (CQA), a national alliance advocating for improvements in the quality of cancer care in America, presents a set of 5 case studies that depict a vision of quality cancer care and a "Blueprint" for actions to realize this vision. |
Testosterone Administration To Men With Testosterone Deficiency Syndrome After External Beam Radiotherapy For Localized Prostate Cancer UroToday.com - Dr. Alvaro Morales and associates from the Centre for Applied Urological Research, reported on the first study on testosterone deficiency syndrome (TDS) in men treated with radiotherapy for prostate cancer. Five men with clinically localized CaP were prospectively studied. The mean Gleason sum was 7 and mean PSA level before radiotherapy was 12.8ng/ml. The mean PSA before testosterone replacement therapy (TRT) was 0.3ng/ml. |
Cytopia Commences Second Phase II Study In Brain Cancer Cytopia Limited (ASX:CYT) announced that it is commencing enrolment for its Phase Ib/II study of CYT997, the company's novel vascular-disrupting anticancer agent, in patients with an aggressive form of brain cancer known as glioblastoma multiforme (GBM). The GBM clinical trial is the first Phase II efficacy study in highly vascular, solid tumour indications for the company and the second in its suite of Phase II studies designed to investigate the anti-cancer activity of CYT997. |
Research Questions Inequality Of Skin Cancer Monitoring For Transplant Patients Kidney transplant patients, one of the most at-risk groups for skin cancer, are not being sufficiently educated or monitored for the disease, according to new research. Kidney transplant recipients are three times more likely to develop skin cancer than people who have not received a transplant. 30 percent of UK renal (kidney) transplant recipients (RTRs) will go on to develop non-melanoma skin cancer, the most common type, within 10 years. |
International Team Reveals First Prognosticator Of Survival In Aggressive Cancer The tumor suppressor gene pRb2/p130 may provide the first independent prognostic biomarker in cases of soft tissue sarcoma (STS), according to an international collaboration of researchers, including scientists at the Sbarro Institute for Cancer Research and Molecular Medicine at the College of |
Few Parents Fear Cervical Cancer Jab Causes Promiscuity In Teens Few parents worry that vaccinating their daughters against human papillomavirus (HPV) and cervical cancer would cause promiscuity. This is the finding of Dr Noel Brewer and colleagues from the University of North Carolina, USA and the Centers for Disease Control who will present their findings on Tuesday 9 September 2008 at the British Psychological Society's Division of Health Psychology's Annual Conference being held at the University of Bath. |
Bladder Tumor Markers: From Hematuria To Molecular Diagnostics - Where Do We Stand? UroToday.com - Bladder cancer is an extremely lethal disease occurring in a large number of patients each year. Most evaluations that result in the diagnosis of bladder cancer are initiated with the finding of either gross or microscopic hematuria. While the majority of patients with hematuria will not have bladder cancer, a sizeable proportion will. |
WHO Proposes Strategy For Prevention And Control Of Cancer In The African Region The World Health Organization (WHO) has proposed a strategy to prevent and control cancer, 582 000 cases of which were recorded in the Region in 2002. Cancer of the cervix, breast, liver and prostate as well as Kaposi's sarcoma and non-Hodgkin's lymphoma are the most common forms of cancer in the African Region. Incidence of these cancers are projected to double by 2020 if effective interventions are not intensified. |
Cellvizio(R) Imaging System Improves Bile Duct Cancer Detection According To A New Study In Clinical Gastroenterology And Hepatology A new imaging system that allows physicians to examine tissue at the cellular level from inside the body may now enable them to more effectively diagnose cancer of the bile ducts, according to a new study in the September 2008 issue of the journal Clinical Gastroenterology and Hepatology. This cancer, medically known as cholangiocarcinoma, is one of the most difficult to detect and treat. |
New Reporting From IntrinsiQ Measures Impact Of Key Events On Oncology Drug Usage IntrinsiQ, LLC, the expert source for clinical oncology insight, launched Event IntelliView, a new analysis tool that quantifies the real-world impact of key events in the lifecycle of medical oncology drugs. Pharmaceutical research teams can now quickly make sense of vast amounts of product performance data, and see how activities like reporting on clinical findings, regulatory approvals and price changes positively or negatively impact market penetration. |
Clinical Trial Protocol Against Cancer Therapy Side Effects (Mucositis) Approved Anadis Ltd. (ASX:ANX; OTC:ANDIY) an Australian biopharmaceutical company specializing in oral immunotherapy using naturally derived antibodies and other proteins is announcing the clinical protocol for its Cancer-related Mucositis Program was cleared by the Tel Aviv Souraski Medical Center's Institutional Review Board (IRB) and by the Israeli Ministry of Health (MOH). This enables the initiation of the clinical trial addressing this significant target at the medical center within a month. |
Height Linked To Risk Of Prostate Cancer Development And Progression A man's height is a modest marker for risk of prostate cancer development, but is more strongly linked to progression of the cancer, say British researchers who conducted their own study on the connection and also reviewed 58 published studies. In the September issue of |
Human Genome Sciences Reports Initial Results Of Randomized Phase 2 Trial Of HGS-ETR1 In Combination With Bortezomib In Advanced Multiple Myeloma Human Genome Sciences, Inc. (Nasdaq: HGSI) reported initial topline results from an ongoing randomized Phase 2 clinical trial of its TRAIL receptor antibody HGS-ETR1 (mapatumumab) in combination with bortezomib (Velcade) in patients with advanced multiple myeloma. The initial data from the multiple myeloma study show that HGS-ETR1 was well tolerated and suggest that disease response was comparable for this combination vs. bortezomib alone. |
Link Between Nationality And Cervical Cancer Gynaecological screening tests for cervical cancer have been available to all women in Sweden for almost four decades. Despite this, many immigrant women have a higher risk of developing the disease than Swedish-born women, according to a new study from the Swedish medical university Karolinska Institutet. |
IU Simon Cancer Center's Tissue Bank Collecting Samples Sept. 20 At Clarian North Would you like to contribute to breast cancer research? You can help by donating a tissue sample to the Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center from 9 a.m. to 2 p.m. Saturday, Sept. 20, at Ology Spa at the Clarian North Medical Center, 11700 North Meridian St., Carmel. A tissue sample will be taken from one breast with a needle and local anesthesia. The amount of tissue taken is about one gram (or the size of two peas). |